Fomepizole
- Generic Name
- Fomepizole
- Brand Names
- Antizol
- Drug Type
- Small Molecule
- Chemical Formula
- C4H6N2
- CAS Number
- 7554-65-6
- Unique Ingredient Identifier
- 83LCM6L2BY
- Background
Fomepizole is used as an antidote in confirmed or suspected methanol or ethylene glycol poisoning. Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial steps in the metabolism of ethylene glycol and methanol to their toxic metabolites.
- Indication
Antizol is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis
- Associated Conditions
- Ethylene glycol poisoning, Methanol poisoning
- Associated Therapies
- -
4-methylpyrazole and Acetaminophen Metabolism
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 6
- Registration Number
- NCT03878693
- Locations
- 🇺🇸
BUMCP - Department of Medical Toxicology, Phoenix, Arizona, United States
Specified Drug-use Survey of Fomepizole Intravenous Infusion (All-case Surveillance)
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 147
- Registration Number
- NCT02415712
- Locations
- 🇯🇵
Takeda Sponsored Site, Tokyo, Japan
Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism
- Conditions
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- Horizon Pharma USA, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00661141
- Locations
- 🇺🇸
Covance Honolulu CRU, Honolulu, Hawaii, United States
Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy
- Conditions
- Interventions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 10
- Registration Number
- NCT00346853
- Locations
- 🇺🇸
Moran Eye Center, University of Utah, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.